Lyell Wealth Management LP Acquires Shares of 6,855 SPDR S&P Biotech (XBI)

Lyell Wealth Management LP bought a new stake in SPDR S&P Biotech (NYSEARCA:XBI) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 6,855 shares of the exchange traded fund’s stock, valued at approximately $593,000.

A number of other large investors have also recently modified their holdings of XBI. Raymond James Financial Services Advisors Inc. raised its holdings in SPDR S&P Biotech by 25.8% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 302,809 shares of the exchange traded fund’s stock worth $26,214,000 after purchasing an additional 62,100 shares in the last quarter. IFC Holdings Incorporated FL raised its holdings in SPDR S&P Biotech by 387.8% during the third quarter. IFC Holdings Incorporated FL now owns 25,722 shares of the exchange traded fund’s stock worth $2,231,000 after purchasing an additional 20,449 shares in the last quarter. Northstar Asset Management LLC acquired a new stake in SPDR S&P Biotech during the third quarter worth approximately $217,000. Pinnacle Advisory Group Inc. raised its holdings in SPDR S&P Biotech by 9.2% during the third quarter. Pinnacle Advisory Group Inc. now owns 7,390 shares of the exchange traded fund’s stock worth $640,000 after purchasing an additional 620 shares in the last quarter. Finally, Financial Sense Advisors Inc. acquired a new stake in SPDR S&P Biotech during the third quarter worth approximately $269,000.

Shares of SPDR S&P Biotech (NYSEARCA:XBI) opened at $81.68 on Wednesday. SPDR S&P Biotech has a 1-year low of $58.66 and a 1-year high of $88.98.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://ledgergazette.com/2017/11/15/lyell-wealth-management-lp-takes-position-in-spdr-sp-biotech-xbi.html.

About SPDR S&P Biotech

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply